| Date | Title | | | December 14, 2017 | Incyte to Present at Upcoming Investor Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 14, 2017--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the 36th Annual J.P. Morgan Healthcare Conference on Monday,
January 8, 2018 at 1:30 pm (PST) in San Francisco.
The presentation and Q&A session will be webcast live and can be
accessed at www.incyte.com
in the Investors section under “Events and Presentations.” Investors
interested in listening to the live webcas... |
|  | | December 10, 2017 | Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi® (ruxolitinib) in Patients with Polycythemia Vera| - Long-term data reinforce Jakafi®
(ruxolitinib) as an effective long-term treatment option for patients
with polycythemia vera (PV) who have had an inadequate response to or
are intolerant of hydroxyurea
- Overall safety profile of Jakafi remained consistent with
previously-reported 80-week RESPONSE data
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 10, 2017--
Incyte Corporation (Nasdaq:INCY) today announced new 208-week (4-year)
fol... |
| | | November 15, 2017 | Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 15, 2017--
Incyte Corporation (Nasdaq:INCY) today announced that the first patient
has been treated in the RESET pivotal trial evaluating ruxolitinib
(Jakafi®) compared to anagrelide for the treatment of
patients with essential thrombocythemia (ET) who are resistant to or
intolerant of hydroxyurea (HU).
“We are pleased to treat the first patient in our pivotal trial
evaluating ruxolitinib as a treatm... |
| | | November 05, 2017 | ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo| - Post-hoc analysis presented at ACR/ARHP shows pain improvement was consistent regardless of a patient's baseline pain severity INDIANAPOLIS, Nov. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that patients with moderate-to-severe rheumatoid arthritis (RA) treated with baricitinib reported greater improvements in pain control when compared to Humira®* (adalimumab) or placebo. A new post-hoc analysis of the Phase 3 RA-BEAM s... |
| | | November 01, 2017 | More Than 30 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 59th Annual ASH Meeting| RESPONSE 4-year follow-up data for Jakafi®
(ruxolitinib) in patients with polycythemia vera accepted as oral
presentation
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 1, 2017--
Incyte Corporation (Nasdaq:INCY) announces that more than 30 abstracts
including data from its clinical development programs for Jakafi® (ruxolitinib),
JAK1, PI3Kδ, PIM and BRD will be presented at the upcoming American
Society of Hematology (ASH) Annual Meeting 2017... |
| | | October 31, 2017 | Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs| $304 million of 2017 third-quarter net product revenues from Jakafi®
(ruxolitinib), representing 36 percent growth over the same period
last year
Progress across the portfolio as multiple candidates enter
late-stage development trials
Two recent collaborations further expand potential and scope of
Incyte’s combination immunotherapy development activities
Conference Call and Webcast Schedu... |
| | | October 31, 2017 | Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Cancer| Phase 3 trial evaluating Imfinzi and epacadostat in patients with
locally-advanced, unresectable non-small cell lung cancer is expected to
begin in first-half 2018
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 31, 2017--
Incyte Corporation (Nasdaq:INCY) and MedImmune, AstraZeneca’s (NYSE:AZN)
global biologics research and development arm, today announced the
expansion of their clinical collaboration. As part of the agreement, the
companies will eval... |
| | | October 30, 2017 | Incyte Names New Member to Its Board of Directors| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 30, 2017--
Incyte Corporation (Nasdaq:INCY) today announced the appointment of
Jacqualyn “Jackie” A. Fouse, Ph.D., as a new member of the Board of
Directors, effective November 14, 2017.
“We are pleased to welcome Jackie to Incyte. Her impressive background
will further strengthen and add to the experience of our Board and
leadership team,” stated Hervé Hoppenot, Incyte’s Chairman and Chief
Executive... |
| | | October 25, 2017 | Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012| Incyte gains exclusive, worldwide development and commercialization
rights to MGA012 in all indications
MacroGenics to receive an upfront cash payment of $150 million plus
potential milestone payments and royalties, and retains right
to develop its pipeline assets in combination with MGA012
WILMINGTON, Del. & ROCKVILLE, Md.--(BUSINESS WIRE)--Oct. 25, 2017--
Incyte Corporation (NASDAQ:INCY) and MacroGenics, Inc. (NA... |
| | | October 24, 2017 | Incyte to Present at Upcoming Investor Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 24, 2017--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the 26th Annual Credit Suisse Healthcare Conference on
Tuesday, November 7, 2017 at 9:45am (MST) in Scottsdale, Arizona.
The presentation will be webcast live and can be accessed at www.incyte.com
under For Investors, Events and Presentations and will be available for
replay for 30 days. Investors interested in listening to ... |
| | | October 12, 2017 | Incyte to Report Third Quarter Financial Results| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 12, 2017--
Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled
its third quarter financial results conference call and webcast for
10:00 a.m. ET on Tuesday, October 31, 2017.
The schedule for the press release and conference call/webcast is as
follows:
• Q3 ... |
| | | October 06, 2017 | Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware| Fund to provide emergency financial support for Delaware cancer
patients and their families
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 6, 2017--
Incyte Corporation (Nasdaq:INCY) and Cancer Support Community Delaware
(CSCDE) today announced the establishment of the Incyte Cancer Care
Assistance Fund for Delaware which will provide emergency financial
assistance for cancer patients, their caregivers and family members
living in Delaware.
T... |
| | | September 14, 2017 | Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis| - Results presented at EADV show baricitinib significantly improved clinical and patient-reported outcomes compared to placebo in moderate-to-severe atopic dermatitis patients
- Improvements seen as early as first week of treatment in baricitinib-treated group
- Lilly will initiate a Phase 3 clinical program for moderate-to-severe atopic dermatitis later this year
INDIANAPOLIS, Sept. 14, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today... |
| | | September 09, 2017 | Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma| Updated Data to be Presented at ESMO 2017 Congress
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 9, 2017--
Incyte Corporation (Nasdaq:INCY) today announced updated data from the
ongoing Phase 1/2 ECHO-202 trial (KEYNOTE-037) evaluating epacadostat,
Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA®
(pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co.,
Inc., Kenilworth, NJ USA (known as MSD outside the United States and
... |
| | | September 09, 2017 | Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma| Updated Data to be Presented at ESMO 2017 Congress
WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Sep. 9, 2017--
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD
outside the United States and Canada, today announced updated data from
the ongoing Phase 1/2 ECHO-202 trial (KEYNOTE-037) evaluating
epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination
with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ... |
| | | September 08, 2017 | Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2017--
Incyte Corporation (Nasdaq: INCY) (the “Company”) today announced the
pricing of its underwritten public offering of 4,945,000 shares of its
common stock. The Company has granted the underwriter an option to
purchase up to an additional 741,750 shares of common stock. The
offering is expected to close on September 12, 2017, subject to
customary closing conditions.
The Company intends to use... |
| | | September 07, 2017 | Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock| WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 7, 2017--
Incyte Corporation (Nasdaq: INCY) (the “Company”) today announced that
the Company intends to offer to sell, subject to market and other
conditions, 4,945,000 shares of its common stock in an underwritten
public offering. In connection with the offering, the Company expects to
grant the underwriter an option to purchase up to an additional 741,750
shares on the same terms and conditions.
Th... |
| | | September 01, 2017 | Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month| New resources are now available to help patients track their
disease and activate the community to increase awareness of rare blood
cancers
Facebook Live Q&A to be held on MPN Awareness Day, September 14,
2017, from 7:00-8:00 p.m. ET
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 1, 2017--
Incyte Corporation (NASDAQ:INCY) is proud to recognize and support the
patients of the MPN community throughout September in ho... |
| | | August 30, 2017 | New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma| Updated Phase 1 and new Phase 2 data from the ECHO-202 trial to be
highlighted as an oral presentation at ESMO 2017 Congress
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 30, 2017--
Incyte Corporation (Nasdaq:INCY) today announced that the European
Society for Medical Oncology (ESMO) has published an abstract (#1214O)
containing new and updated data from the ongoing Phase 1/2 ECHO-202
trial evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor,
... |
| | | August 30, 2017 | Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018| INDIANAPOLIS , Aug. 30, 2017 /PRNewswire/ -- Eli Lilly and Company ( NYSE : LLY) and Incyte Corporation (NASDAQ: INCY) announced today that, after discussions with the U.S. Food and Drug Administration (FDA) in late August, Lilly will resubmit the New Drug Application (NDA) for baricitinib before the end of January 2018 . The resubmission package will include new safety and efficacy data. The companies anticipate the FDA will classify the application ... |
| | | August 10, 2017 | Forbes Magazine Names Incyte One of the World’s Most Innovative Companies for Third Consecutive Year| Company ranked 6th in 2017 and in Top 10 for Third Year Running
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 10, 2017--
Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 6th on Forbes magazine’s
2017 list of the World’s Most Innovative Companies. Incyte, a
biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics, is advancing an
innovative and diverse portfolio of large and small m... |
| | | August 01, 2017 | Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs| $276 million of 2017 second-quarter net product revenues from Jakafi®
(ruxolitinib), representing 33 percent growth over the same period
last year
Proof-of-concept data for the combination of epacadostat plus PD-1
inhibition presented at the American Society of Clinical Oncology
Annual Meeting (ASCO) 2017 across multiple tumor types; expanded Phase
3 program on track for planned initiation in 2017
Mult... |
| | | July 25, 2017 | Lilly and Incyte Provide Update on Baricitinib| INDIANAPOLIS , July 25, 2017 /PRNewswire/ -- Eli Lilly and Company ( NYSE : LLY) and Incyte Corporation (NASDAQ: INCY) announced today that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA), will be delayed beyond 2017. The companies will be further discussing the path forward with the agency and evaluating options for resubmiss... |
| | | July 20, 2017 | Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease| WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 20, 2017--
Incyte Corporation (Nasdaq:INCY) today announced that the first patient
has been treated in GRAVITAS-301, a pivotal Phase 3 trial for the
first-line treatment of patients with acute graft-versus-host disease
(GVHD). The trial will evaluate the efficacy and safety of itacitinib,
Incyte’s novel, potent, and selective JAK1 inhibitor, in combination
with corticosteroids compared to placebo plus corticosteroi... |
| | | July 11, 2017 | Incyte to Report Second Quarter Financial Results| WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 11, 2017--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its second quarter financial results conference call and webcast for
10:00 a.m. ET on Tuesday, August 1, 2017.
The schedule for the press release and conference call/webcast is as
follows:
... |
| | | July 03, 2017 | Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis| INDIANAPOLIS, July 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant® (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis (RA) (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies. The Olumiant approval is based on the results of the barici... |
| | | June 16, 2017 | New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017| INDIANAPOLIS, June 16, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced a new pooled analysis of data from eight Olumiant® (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis (RA) had similar rates of serious infection incidents. Additionally, new data from the long-term extension (LTE) of Phase 3 trials showed that two years of baricitinib treatment sig... |
| | | June 13, 2017 | Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)| INDIANAPOLIS, June 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data on safety and long-term efficacy from the Olumiant® (baricitinib) clinical trials will be presented in 21 abstracts, including one oral presentation, at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid, June 14-17, 2017. Lilly will also present six abstracts evaluating Taltz® (ixekizumab) for the treatment of psoriatic arthri... |
| | | June 07, 2017 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 7, 2017--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the following investor conferences during the month of June:
Goldman Sachs 38th Annual Global Healthcare Conference on
Wednesday, June 14, 2017 at 10:40 am (PDT) / 1:40 pm (EDT) in Rancho
Palos Verdes;
William Blair 2017 Growth Stock Conference on Wednesday, June 14, 2017
at 10:00 am (... |
| | | June 05, 2017 | Incyte Analyst and Investor Event to Highlight Clinical Data Presentations from ASCO 2017| WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 5, 2017--
Incyte Corporation (Nasdaq:INCY) announced today that data from ongoing
investigational studies of epacadostat in combination with pembrolizumab
(ECHO-202) and nivolumab (ECHO-204) in multiple tumor types will be
discussed at an Analyst and Investor Event this evening, Monday, June 5,
2017. These data are from posters and presentations at the American
Society for Clinical Oncology (ASCO) Annual Meeting be... |
| | | June 05, 2017 | Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer| These data supported advancing the clinical development program for
epacadostat and Opdivo in these types of cancer
Combination of IDO1 enzyme inhibition plus Opdivo was generally
well-tolerated in patients with select advanced solid tumors
WILMINGTON, Del. & and NEW YORK--(BUSINESS WIRE)--Jun. 5, 2017--
Incyte Corporation (Nasdaq:INCY) and Bristol-Myers Squibb Company
(NYSE:BMY) today announced updated data from the ongoing Phase 1/2
... |
| | | June 05, 2017 | Updated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types| Responses observed with combination of IDO1 enzyme inhibition and
anti-PD-1 therapy support advancing into broad Phase 3 program
Safety data for this novel investigational immunotherapy combination
are generally similar to KEYTRUDA monotherapy
WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jun. 5, 2017--
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD
outside the United States and Canada, today announced that up... |
| | | June 03, 2017 | Combination of Epacadostat plus Keytruda® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)| Updated Phase 1/2 data from ECHO-202 investigating the combination of
IDO1 enzyme inhibition and anti-PD-1 therapy in patients with advanced
NSCLC, regardless of PD-L1 status, presented at 2017 ASCO Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 3, 2017--
Incyte Corporation (NASDAQ:INCY) today announced updated data from the
advanced non-small cell lung cancer (NSCLC) patient cohort of the
ongoing Phase 1/2 ECHO-202 trial, evaluating epacados... |
| | | June 03, 2017 | Combination of Incyte’s Epacadostat plus Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)| Updated Phase 1/2 data from ECHO-202 investigating the combination of
IDO1 enzyme inhibition and anti-PD-1 therapy in patients with advanced
NSCLC, regardless of PD-L1 status, presented at 2017 ASCO Annual Meeting
WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jun. 3, 2017--
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD
outside the United States and Canada, today announced updated data from
the advanced non-small cell... |
| | | May 22, 2017 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--May 22, 2017--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the following investor conferences during the month of June:
William Blair 2017 Growth Stock Conference on Wednesday, June 14, 2017
at 10:00 am (CDT) in Chicago; and
Nasdaq 36th Investor Program on Thursday, June 15, 2017 at
11:00 am (BST) in London
The presentations will... |
| | | May 17, 2017 | New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda® (pembrolizumab)| Incyte’s IDO1 enzyme inhibitor in combination with Merck’s anti-PD-1
therapy is well-tolerated and demonstrates durable clinical responses
across multiple solid tumors
WILMINGTON, Del.--(BUSINESS WIRE)--May 17, 2017--
Incyte Corporation (Nasdaq:INCY) today announced the publication of new
data from the ongoing ECHO-202 trial, evaluating epacadostat, Incyte’s
selective IDO1 enzyme inhibitor, in combination with Keytruda®
(pembrolizumab), Merck’... |
| | | May 17, 2017 | First Data from Combination of Epacadostat with Opdivo® (nivolumab) Will Be Highlighted at ASCO 2017| Combination is well-tolerated and demonstrates promising clinical
outcomes in multiple advanced solid tumors
WILMINGTON, Del.--(BUSINESS WIRE)--May 17, 2017--
Incyte Corporation (Nasdaq:INCY) today announced that the American
Society of Clinical Oncology (ASCO) has published Phase 1/2 data from
the ongoing ECHO-204 trial evaluating the safety and efficacy of
epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination
with Opdivo® (ni... |
| | | May 04, 2017 | Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs| $251 million of 2017 first-quarter net product revenues from Jakafi®
(ruxolitinib), representing 37 percent growth over the same period
last year
Expanded ECHO program for epacadostat to include multiple pivotal
trials in patients with melanoma, non-small cell lung, head & neck,
bladder, and renal cancers in combination with PD-1 inhibitors
Olumiant® (baricitinib) approved by the
European Commissio... |
| | | April 25, 2017 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 25, 2017--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the following investor conferences during the month of May:
Bank of America Merrill Lynch 2017 Health Care Conference on
Wednesday, May 17, 2017 at 10:00 am (PDT) in Las Vegas; and
UBS Global Healthcare Conference on Monday, May 22, 2017 at 11:30 am
(EDT) in New York
The... |
| | | April 20, 2017 | Incyte's Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured in More than 15 Abstracts at the 2017 ASCO Annual Meeting| Presentations to include data from the ECHO-202 trial of epacadostat
plus KEYTRUDA® (pembrolizumab) and initial data
from the ECHO-204 trial of epacadostat plus Opdivo®
(nivolumab)
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 20, 2017--
Incyte Corporation (Nasdaq: INCY) announces that more than 15 abstracts
highlighting its research and development portfolio in immuno-oncology
and targeted therapies will be presented at the upcoming 2017 American
... |
| | | April 18, 2017 | Incyte to Report First Quarter Financial Results| WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 18, 2017--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its first quarter financial results conference call and webcast for
10:00 a.m. ET on Thursday, May 4, 2017.
The schedule for the press release and conference call/webcast is as
follows:
• Q1 2017 Press Release:
... |
| | | April 14, 2017 | U.S. FDA Issues Complete Response Letter for Baricitinib| INDIANAPOLIS--(BUSINESS WIRE)--Apr. 14, 2017--
Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY)
announced today that the U.S. Food and Drug Administration (FDA) has
issued a complete response letter for the New Drug Application (NDA) of
the investigational medicine baricitinib, a once-daily oral medication
for the treatment of moderate-to-severe rheumatoid arthritis (RA).
This Smart News Release features multimedia. View the full r... |
| | | April 02, 2017 | Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials | Companies to initiate Phase 3 registrational trials in first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017 Collaboration will add additional I-O relapsed/refractory melanoma cohorts to ECHO-204, the ongoing Phase 1/2 multi-tumor study of epacadostat plus Opdivo NEW YORK & WILMINGTON, Del.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Incyte Corporation (Na... |
| | | March 31, 2017 | Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)| Clinical Program Now Includes Seven Registrational Trials Across Five
Tumor Types
WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Mar. 31, 2017--
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD
outside the United States and Canada, today announced additional details
of their clinical development program investigating the combination of
epacadostat, Incyte’s investigational oral selective IDO1 enzyme
inhibitor, wit... |
| | | March 02, 2017 | Incyte’s Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abstracts at the AACR Annual Meeting 2017| WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 2, 2017--
Incyte Corporation (Nasdaq:INCY) announces that 20 abstracts from its
research and development portfolio will be presented at the upcoming
2017 American Association for Cancer Research (AACR) annual meeting in
Washington, D.C. from April 1-5, 2017. These abstracts include a
clinical data presentation from the dose-escalation phase of the
Company’s ongoing trial of its selective FGFR 1/2/3 inhibitor
... |
| | | February 28, 2017 | Incyte Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disease Day 2017| February 28, 2017, commemorates the tenth annual Rare Disease Day
Incyte supports efforts to raise awareness and improve diagnosis and
treatment for the nearly 200,000 people in the United States with MPNs,
a group of rare blood cancers
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 28, 2017--
Incyte Corporation (Nasdaq:INCY) joins the National Organization for
Rare Disorders (NORD), the European Organization for Rare Diseases
(EURODI... |
| | | February 23, 2017 | Incyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania| Collaboration aims to advance the understanding of cancer biology and
foster innovative science in immunotherapy
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 23, 2017--
Incyte Corporation (Nasdaq:INCY) today announces a multi-year research
collaboration with the Abramson Cancer Center at the University of
Pennsylvania. Through this collaboration, Incyte and Abramson have
agreed to bring together the knowledge and expertise of their leading
drug dis... |
| | | February 21, 2017 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 21, 2017--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the following investor conferences during the month of March:
Cowen and Company 37th Annual Health Care Conference on
Wednesday, March 8, 2017 at 10:00 am (EST) in Boston; and
Barclays Capital Global Healthcare Conference on Wednesday, March 15,
2017 at 2:35 pm (EDT) in Miami
... |
| | | February 15, 2017 | Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo| INDIANAPOLIS ,Feb. 15, 2017/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) – were published in the New England Journal of Medicine.The New England Journal of Medicine publication includes supplementary data, which show that starting as early as week 8, and sustained through week 52, a h... |
| | | February 14, 2017 | Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs| $238 million of 2016 fourth-quarter net product revenues from Jakafi®
(ruxolitinib), representing 30 percent growth over the same period
last year and $853 million of 2016 full-year net product revenues from
Jakafi, representing 42 percent growth over last year
Multiple pivotal programs expected to commence this year, including
the combination of epacadostat and pembrolizumab in four additional
solid tumor indications
... |
| | | February 14, 2017 | Incyte and Agenus Amend Collaboration Agreement| Incyte secures global clinical development and commercialization
responsibilities for GITR and OX40 programs, converting both from
profit-sharing to royalty-bearing arrangements
Agenus to receive $80 million from Incyte: $60 million equity
investment at $6 per share and $20 million in accelerated clinical
development milestones
WILMINGTON, Del. & LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 14, 2017--
Incyte Corporation (Nasdaq:INCY) an... |
| | | February 13, 2017 | European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis| Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU
INDIANAPOLIS, Feb. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Commission has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or w... |
| | | January 30, 2017 | Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor| Incyte gains worldwide rights to CB-1158 for hematology and
oncology indications
Calithera to receive a $45 million up-front payment and an $8
million equity investment
Incyte and Calithera to co-fund global development of CB-1158;
Calithera eligible to receive share of profits in the U.S., potential
milestones and royalties on future sales of CB-1158
Calithera conference call scheduled... |
| | | January 24, 2017 | Incyte to Report Fourth Quarter and Year-End Financial Results| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 24, 2017--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its fourth quarter and year end 2016 financial results conference call
and webcast for 10:00 a.m. ET on Tuesday, February 14, 2017.
The schedule for the press release and conference call/webcast is as
follows:
... |
| | | January 13, 2017 | U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment| INDIANAPOLIS, Jan. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis (RA). The NDA for baricitinib was submitted to the FDA in January 2016.The FDA extended the action date to allow time to review ... |
| | | January 09, 2017 | Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)| Additional pivotal studies evaluating Incyte’s IDO1 inhibitor in
combination with Merck’s anti-PD-1 therapy in patients with non-small
cell lung, renal, bladder and head and neck cancers expected to start in
2017
WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jan. 9, 2017--
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD
outside the United States and Canada, today announced the decision to
advance the clinical de... |
| |
|
